Literature DB >> 14671809

[Pharmacotherapy of rheumatic diseases in the aged].

S Kary1, F Buttgereit, G R Burmester.   

Abstract

The optimal drug therapy of inflammatory rheumatic diseases is based on an individual concept of treatment combining several antirheumatic drugs with different modes of acting. In treating older patients this individual concept has to consider special conditions, as these patients often receive further medications due to different indications so that pharmacologic interactions and comorbidity have to be taken into account. Recently, new substances like COX-2-inhibitors, the new disease modifying antirheumatic drug (DMARD) Leflunomide and particularly the cytokine-blockers provide new and highly effective treatment options. The administration of these drugs in elderly patients is discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14671809     DOI: 10.1007/s00108-003-0940-6

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  8 in total

Review 1.  The use of leflunomide in the treatment of rheumatoid arthritis: an experimental and clinical review.

Authors:  M Schattenkirchner
Journal:  Immunopharmacology       Date:  2000-05

2.  Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis.

Authors:  L W Moreland; S B Cohen; S W Baumgartner; E A Tindall; K Bulpitt; R Martin; M Weinblatt; J Taborn; A Weaver; D J Burge; M H Schiff
Journal:  J Rheumatol       Date:  2001-06       Impact factor: 4.666

Review 3.  Leflunomide and rheumatoid arthritis: a systematic review of effectiveness, safety and cost implications.

Authors:  P J Hewitson; S Debroe; A McBride; R Milne
Journal:  J Clin Pharm Ther       Date:  2000-08       Impact factor: 2.512

Review 4.  Geropharmacology for the rheumatologist.

Authors:  L A Percy; M A Fang
Journal:  Rheum Dis Clin North Am       Date:  2000-08       Impact factor: 2.670

5.  Safety of low dose methotrexate in elderly patients with rheumatoid arthritis.

Authors:  B Hirshberg; M Muszkat; O Schlesinger; A Rubinow
Journal:  Postgrad Med J       Date:  2000-12       Impact factor: 2.401

Review 6.  Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis.

Authors:  M H Schiff; A Whelton
Journal:  Semin Arthritis Rheum       Date:  2000-12       Impact factor: 5.532

Review 7.  [Present position in the prevention and therapy of NSAID-induced ulcers].

Authors:  F S Lehmann; C Beglinger
Journal:  Schweiz Med Wochenschr       Date:  1999-07-27

Review 8.  Disease-modifying antirheumatic drugs. Potential effects in older patients.

Authors:  G Gardner; D E Furst
Journal:  Drugs Aging       Date:  1995-12       Impact factor: 3.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.